Search Results - "Milburn, Michael Vance"

Development of a novel RNA-based immune checkpoint inhibitor response signature (ICI-PRS) that avoids standard-of-care (SOC) prognostic signal for use in patients with urothelial cancer (UC) by Shepherd, Jonathan, Mayhew, Gregory, Guo, John, Beebe, Kirk, Eisner, Joel Robert, Milburn, Michael Vance

“…549 Background: Immune checkpoint inhibition (ICI) shows great promise, including approval of pembrolizumab, nivolumab and avelumab in urothelial cancer (UC)…”
Get full text

Development of a novel RNA-based fibroblast growth factor receptor response signature (FGFR-PRS) for use in patients with urothelial cancer (UC) by Pappan, Kirk L., Mayhew, Gregory, Davison, James M., Shibata, Yoichiro, Eisner, Joel Robert, Beebe, Kirk, Milburn, Michael Vance

“…548 Background: Interest in FGFR-targeted (FGFRi) therapies for UC or pan-tumor use is growing (ongoing clinical studies include erdafitinib (NCT05316155;…”
Get full text

Molecular characterization of advanced muscle invasive bladder cancer (MIBC): Comparison of low-input targeted RNA sequencing (RNAseq) strategies by Shibata, Yoichiro, Uronis, Joshua M., Conroy, Jeffrey M., Glenn, Sean, Guo, John, Mayhew, Gregory, Eisner, Joel Robert, Milburn, Michael Vance

“…Abstract only 564 Background: 5-year survival for advanced MIBC is poor (~5%), but newer targeted agents (e.g., PD-1/PD-L1 or FGFR) have improved survival over…”
Get full text

Detailed immunogenomic analysis of high dose IL-2 pharmacodynamic effects: A benchmark for next-generation IL-2-based immunotherapies by Beebe, Kirk, Eisner, Joel Robert, Shibata, Yoichiro, Davison, James M, Guo, John, Farhangfar, Carol J., Farhangfar, Farhang, Uronis, Joshua M., Mooney, Jill, Milburn, Michael Vance, Foureau, David, White, Richard L., Amin, Asim, Milla, Marcos E

“…e16501 Background: High-dose interleukin-2 (HD IL-2) was the first approved immune-oncology (IO) agent based on proven clinical efficacy in renal cell…”
Get full text

RNAseq and DNA whole-exome sequence analysis reveal novel response signatures to IO treatment in muscle invasive bladder cancer (MIBC) patients by Mayhew, Gregory, Shibata, Yoichiro, Uronis, Joshua M, Hayward, Michele C, Rose, Tracy L, Kim, William Y., Perou, Charles M., Lai-Goldman, Myla, Milburn, Michael Vance

“…Abstract only 4558 Background: Objective: To examine in a cohort of anti-PD-(L)1 immune checkpoint inhibitors (ICP) treated urothelial cancer patients a…”
Get full text